Sanofi appoints Yong-Jun Liu as head of research

29 March 2016

French pharma giant Sanofi (Euronext: SAN) has announced the appointment of leading immunology researcher Yong-Jun Liu as its head of research.

Dr Liu, who has more than 94,000 citations and in excess of 250 prominent journal articles to his name, will take up the role from Friday, reporting to Elias Zerhouni, president of Sanofi Global Research and Development.

After receiving doctorates from universities in both China and the UK, Dr Liu’s research has led to the development of several key drug targets in immunology, oncology and for allergies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical